Intec Pharma partners for manufacture of ‘accordion pill’ for Parkinson’s disease

Intec Pharma (NSDQ:NTEC) plans to partner with LTS to manufacture the company’s lead product candidate – an oral pill for Parkinson’s disease formulated with Intec’s “Accordion Pill” drug delivery tech.

According to the terms of the deal, LTS will manufacture the carbidopa/levodopa capsules using Intec’s production technology in LTS’ manufacturing facility in Germany.

Intec is working to produce enough of its lead candidate for a Phase III trial in its own Jerusalem-based manufacturing facility.

“We are particularly pleased to be partnering with LTS, a global leader in the commercial manufacture of formulation and film technologies for the pharmaceutical industry. This is a key achievement for Intec as we near completion of our pivotal Phase III Accordance clinical trial in advanced Parkinson’s Disease patients and advance our pre-commercial strategies for AP-CD/LD,” CEO Jeffrey Meckler said in prepared remarks.

“Built on nearly ten years of research and development, our state-of-the art and proprietary manufacturing process for the Accordion Pill is in good hands with LTS and its team of experts at it cGMP facilities,” COO Nadav Navon added.

“LTS is highly committed to contribute to the innovative opportunities of the Accordion Pill technology for Carbidopa/Levodopa. LTS’ well proven capabilities in the scale-up and large volume manufacture meet Intec´s requirements for a reliable supply that conforms with the most stringent quality requirements,” Michael Hoffmann, chief technology & operating officer for LTS, said.

Intec’s Accordion Pill is made of biodegradable polymeric films that fold into an accordion shape and fit into a standard-sized oral capsule.

When the capsule reaches a patient’s stomach, it dissolves and the Accordion Pill unfolds to remain in the stomach for up to 12 hours, releasing drug towards the upper part of the GI tract.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Inside Hologic's evolving definition of women's healthcare Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business. At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it! REGISTER NOW Use code WOMENSHEALTH to save an additional 10%.